News | News By Subject | News by Disease News By Date | Search News

Rheumatoid arthritis News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Market Just Got More Crowded as Regeneron (REGN), Sanofi (SNY)'s New RA Drug Wins FDA Approval     5/24/2017
FDA Just Rejected Eli Lilly (LLY), Incyte (INCY)'s Rheumatoid Arthritis Drug Baricitinib     4/18/2017
Success of Pfizer (PFE)’s Humira Biosimilar for Rheumatoid Arthritis in Phase III Bodes Well for Its Strong Biosimilar Pipeline     1/23/2017
Going Up Against AbbVie (ABBV)'s Humira, Johnson & Johnson (JNJ) Presents Less-Than-Stellar Phase III Data     11/14/2016
OUCH! FDA Spurns Regeneron (REGN), Sanofi (SNY)'s RA Drug Over Plant Deficiencies     11/1/2016
Deficiencies Found at Manufacturing Site Could Delay Approval of Sanofi Genzyme (SNY)'s Next Blockbuster     10/31/2016
AbbVie (ABBV) Abandons Arthritis Pact With Ablynx (ABLYF)     10/20/2016
3 Healthcare Giants Are All Trying to Take a Bite Out of AbbVie (ABBV)'s Humira Domination     10/14/2016
FDA Clears Amgen (AMGN) Copy of AbbVie (ABBV)'s Blockbuster Humira     9/26/2016
Ablynx (ABLYF) Reports Compelling Topline Phase Ilb Study Results With Its Anti-Il-6r Nanobody, Vobarilizumab, In RA Patients, Confirming Its Best-In-Class Potential     8/9/2016
GlaxoSmithKline (GSK) Becomes First Drug Firm to Use Apple (AAPL)’s ResearchKit for Clinical Research     7/18/2016
Amgen (AMGN) Inches Closer to Selling Cheaper Version of AbbVie (ABBV)'s Blockbuster Humira     7/13/2016
FDA Staff Says Novartis AG (NVS) Copy of Amgen (AMGN)'s Blockbuster Enbrel is 'Highly Similar'     7/11/2016
AbbVie (ABBV)'s $175 Million Gamble Pays Off as Ablynx (ABLYF) RA Drug Meets Goal in Phase II Study     7/8/2016
FDA Staff Says Amgen (AMGN) Biosimilar is 'Highly Similar' to AbbVie (ABBV)'s Blockbuster Humira     7/8/2016

News from Around the Web
Eli Lilly (LLY) Gives No New Information On Rheumatoid Arthritis Drug Delay     4/26/2017
How AbbVie (ABBV), Gilead (GILD), Pfizer (PFE) Are All Gaining From Eli Lilly (LLY)'s RA Rejection Pain     4/18/2017
Vagus Nerve Stimulation Significantly Reduces Rheumatoid Arthritis Symptoms, University of Amsterdam Study Shows     7/5/2016
Green Tea Compound May Block Rheumatoid Arthritis, Washington State University Study     2/17/2016
Occupational Textile Dust Exposure Linked To Rheumatoid Arthritis, Study Published In BMJ     1/15/2016
Your Diet May Determine Rheumatoid Arthritis Risk, Brigham and Women's Hospital Study     11/9/2015
Could Oral Contraceptives Help Ease Rheumatoid Arthritis? Rheumatism Research Centre Study     8/31/2015
Drug Flops From 2004 Haunt AstraZeneca PLC (AZN) Investors     5/23/2014
Chinese Herb As Effective As Arthritis Pain Drug, Annals of the Rheumatic Diseases Reveals     4/16/2014
Extra Pounds Linked to Rheumatoid Arthritis Risk in Women, Brigham and Women's Hospital, Harvard Medical School, Harvard School of Public Health Reveals     11/12/2012
Rheumatoid Arthritis Drugs May Help Curb Diabetes Development, Journal of the American Medical AssociationStudy Finds     6/22/2011
EULAR: Rituximab Plus Other Biologics Safe in RA     6/1/2011
Study Identifies Novel Role for a Protein That Could Lead to New Treatments for Rheumatoid Arthritis, Hospital for Special Surgery Study     5/23/2011
Lupus, Rheumatoid Arthritis May Raise Risk of Abnormal Heart Rhythm, University of Arkansas for Medical Sciences Study     5/9/2011
Recent Rituximab Trial with TNF Inhibitors Reports No New Safety Risks in Patients with Rheumatoid Arthritis, Desert Medical Advances Study     3/8/2011

Press Releases
CEL-SCI (CVM) Scientist Presents At AAI - IMMUNOLOGY 2017 Meeting     5/16/2017
twoXAR To Present Data From In Vivo Studies Investigating New Rheumatoid Arthritis Drug Candidates At IMMUNOLOGY 2017     5/3/2017
Sanofi (SNY) Release: Survey Results Show Eighty Percent Of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily Or Multiple Times A Week, Despite Treatment     5/2/2017
Sanofi (SNY) And Regeneron (REGN) Announce Kevzara (Sarilumab) Biologics License Application Resubmission Accepted For Review By The FDA     4/28/2017
Can-Fite BioPharma (CFBI)'s Phase III ACRobat Trial In Rheumatoid Arthritis Approved By Institutional Review Board     4/25/2017
Samsung Bioepis Obtains First Drug Approval In The United States, As FDA Approves RENFLEXIS (Infliximab-Abda) Across All Eligible Indications     4/24/2017
Regeneron (REGN) And Sanofi (SNY) Receive Positive CHMP Opinion For Kevzara (Sarilumab) To Treat Adult Patients With Moderately To Severely Active Rheumatoid Arthritis     4/24/2017
Sanofi (SNY) And Regeneron (REGN) Receive CHMP Positive Opinion For Kevzara (Sarilumab) To Treat Adult Patients With Moderately To Severely Active Rheumatoid Arthritis     4/24/2017
JHL Biotech Doses First Patient In JHL1101 Phase I European Trial     3/29/2017
New Potential Treatment For Rheumatoid Arthritis Uncovered By Scientists At Lankenau Institute for Medical Research     3/28/2017
Pfizer (PFE) Release: XELJANZ (Tofacitinib Citrate) Receives Marketing Authorisation In The European Union For The Treatment Of Moderate To Severe Active Rheumatoid Arthritis (RA)     3/27/2017
Pfizer (PFE) Announces Approval By The China Food And Drug Administration Of XELJANZ, The First Oral JAK Inhibitor For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis     3/16/2017
Celltex Therapeutics Corporation Autologous Stem Cell Case Study Published In Stem Cells And Development Demonstrates Favorable Response In Pediatric Patients     3/13/2017
Sanofi Genzyme (SNY) Release: Kevzara (Sarilumab) Now Available In Canada For The Treatment Of Adult Patients With Moderately To Severely Active Rheumatoid Arthritis     2/28/2017
CEL-SCI (CVM) Scientist Presents New Findings For Rheumatoid Arthritis Treatment Vaccine At Conference     2/21/2017

//-->